{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:19:39Z","timestamp":1790803179214,"version":"4.1.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2017,9,1]],"date-time":"2017-09-01T00:00:00Z","timestamp":1504224000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","ijaaonline.com","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1016\/j.ijantimicag.2017.04.014","type":"journal-article","created":{"date-parts":[[2017,6,27]],"date-time":"2017-06-27T17:48:20Z","timestamp":1498585700000},"page":"427-435","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":49,"title":["Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens"],"prefix":"10.1016","volume":"50","author":[{"given":"Joanna E.","family":"Payne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice V.","family":"Dubois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca J.","family":"Ingram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead","family":"Weldon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford C.","family":"Taggart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Stuart","family":"Elborn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Tunney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0010","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1016\/S0140-6736(09)60327-5","article-title":"Cystic fibrosis","volume":"373","author":"O'Sullivan","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0015","series-title":"UK cystic fibrosis registry 2015 annual data report","author":"Carr","year":"2016"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0020","doi-asserted-by":"crossref","first-page":"e0116029","DOI":"10.1371\/journal.pone.0116029","article-title":"Comparison of microbiomes from different niches of upper and lower airways in children and adolescents with cystic fibrosis","volume":"10","author":"Boutin","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0025","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1136\/thx.2010.137281","article-title":"Use of culture and molecular analysis to determine the effect of antibiotic treatment on microbial community diversity and abundance during exacerbation in patients with cystic fibrosis","volume":"66","author":"Tunney","year":"2011","journal-title":"Thorax"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0030","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ppul.21198","article-title":"Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008","volume":"45","author":"Emerson","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0035","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1378\/chest.06-2888","article-title":"Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis","volume":"132","author":"Merlo","year":"2007","journal-title":"Chest"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0040","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/S0140-6736(14)61137-5","article-title":"Antimicrobial resistance in the respiratory microbiota of people with cystic fibrosis","volume":"384","author":"Sherrard","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0045","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/ppul.21011","article-title":"Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients","volume":"44","author":"Bjarnsholt","year":"2009","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0050","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1038\/35037627","article-title":"Quorum-sensing signals indicate that cystic fibrosis lungs are infected with bacterial biofilms","volume":"407","author":"Singh","year":"2000","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.ijantimicag.2017.04.014_bib0055","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005405.pub4","article-title":"Oral anti-pseudomonal antibiotics for cystic fibrosis","author":"Remmington","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0060","doi-asserted-by":"crossref","first-page":"6735","DOI":"10.1128\/AAC.01046-16","article-title":"Antimicrobial susceptibility of Pseudomonas aeruginosa isolated from cystic fibrosis patients through Northern Europe","volume":"60","author":"Mustafa","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0065","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.coph.2006.04.006","article-title":"Antibacterial peptides for therapeutic use: obstacles and realistic outlook","volume":"6","author":"Marr","year":"2006","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0070","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1476-9255-10-15","article-title":"Histone deacetylase inhibitors up-regulate LL-37 expression independent of Toll-like receptor mediated signalling in airway epithelial cells","volume":"10","author":"Liu","year":"2013","journal-title":"J Inflamm (Lond)"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0075","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1042\/BST0391437","article-title":"SLPI and elafin: multifunctional antiproteases of the WFDC family","volume":"39","author":"Scott","year":"2011","journal-title":"Biochem Soc Trans"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0080","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1046\/j.1365-2567.2002.01430.x","article-title":"Expression of \u03b2-defensin 1 and 2 mRNA by human monocytes, macrophages and dendritic cells","volume":"106","author":"Duits","year":"2002","journal-title":"Immunology"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0085","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1006\/bbrc.1998.9069","article-title":"Antileukoprotease in human skin: an antibiotic peptide constitutively produced by keratinocytes","volume":"248","author":"Wiedow","year":"1998","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0090","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1096\/fj.00-0865fje","article-title":"Human \u03b2-defensin 4: a novel inducible peptide with a specific salt-sensitive spectrum of antimicrobial activity","volume":"15","author":"Garc\u00eda","year":"2001","journal-title":"FASEB J"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0095","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.1128\/IAI.71.7.3730-3739.2003","article-title":"Staphylococcus aureus susceptibility to innate antimicrobial peptides, \u03b2-defensins and CAP18, expressed by human keratinocytes","volume":"71","author":"Midorikawa","year":"2003","journal-title":"Infect Immun"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0100","doi-asserted-by":"crossref","first-page":"2838","DOI":"10.1128\/AAC.45.10.2838-2844.2001","article-title":"Cathelicidin peptides inhibit multiply antibiotic-resistant pathogens from patients with cystic fibrosis","volume":"45","author":"Saiman","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0105","doi-asserted-by":"crossref","first-page":"18825","DOI":"10.1073\/pnas.0904709106","article-title":"Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770","volume":"106","author":"Van Goor","year":"2009","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0110","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1056\/NEJMoa1105185","article-title":"A CFTR potentiator in patients with cystic fibrosis and the G551D mutation","volume":"365","author":"Ramsey","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0115","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jcf.2014.02.004","article-title":"Antibacterial properties of the CFTR potentiator ivacaftor","volume":"13","author":"Reznikov","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0120","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1164\/rccm.200708-1151OC","article-title":"Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis","volume":"177","author":"Tunney","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0125","first-page":"169","article-title":"Designer assays for antimicrobial peptides. Disputing the \u2018one-size-fits-all\u2019 theory","volume":"78","author":"Steinberg","year":"1997","journal-title":"Methods Mol Biol"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0130","series-title":"Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A","author":"Clinical and Laboratory Standards Institute","year":"1999"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0135","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0167-7012(00)00122-6","article-title":"A modified microtiter-plate test for quantification of staphylococcal biofilm formation","volume":"40","author":"Stepanovi\u0107","year":"2000","journal-title":"J Microbiol Methods"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0140","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1128\/AAC.00653-15","article-title":"Bactericidal activity of ceragenin CSA-13 in cell culture and in an animal model of peritoneal infection","volume":"59","author":"Bucki","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.peptides.2014.09.021","article-title":"Inhibition and destruction of Pseudomonas aeruginosa biofilms by antibiotics and antimicrobial peptides","volume":"62","author":"Dosler","year":"2014","journal-title":"Peptides"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0150","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1164\/rccm.201404-0703OC","article-title":"Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis","volume":"190","author":"Rowe","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0155","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1093\/cid\/ciu944","article-title":"Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor","volume":"60","author":"Heltshe","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0160","doi-asserted-by":"crossref","first-page":"e0124124","DOI":"10.1371\/journal.pone.0124124","article-title":"Impact of the CFTR-potentiator ivacaftor on airway microbiota in cystic fibrosis patients carrying a G551D mutation","volume":"10","author":"Bernarde","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0165","series-title":"Approval package for: application number 203188Orig1s000","author":"Raggio","year":"2012"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0170","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.jcf.2015.02.010","article-title":"Alterations in blood leukocytes of G551D-bearing cystic fibrosis patients undergoing treatment with ivacaftor","volume":"15","author":"Bratcher","year":"2015","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0175","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s15010-005-8209-8","article-title":"Immunomodulatory activities of fluoroquinolones","volume":"33","author":"Dalhoff","year":"2005","journal-title":"Infection"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0180","doi-asserted-by":"crossref","first-page":"e58389","DOI":"10.1371\/journal.pone.0058389","article-title":"Ciprofloxacin modulates cytokine\/chemokine profile in serum, improves bone marrow repopulation, and limits apoptosis and autophagy in ileum after whole body ionizing irradiation combined with skin-wound trauma","volume":"8","author":"Fukumoto","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0185","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0092-8674(00)81895-4","article-title":"Human \u03b2-defensin-1 is a salt-sensitive antibiotic in lung that is inactivated in cystic fibrosis","volume":"88","author":"Goldman","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0190","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1183\/09031936.00080806","article-title":"Release of the antimicrobial peptide LL-37 from DNA\/F-actin bundles in cystic fibrosis sputum","volume":"29","author":"Bucki","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2017.04.014_bib0195","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1096\/fj.05-4406com","article-title":"The mammalian ionic environment dictates microbial susceptibility to antimicrobial defense peptides","volume":"20","author":"Dorschner","year":"2006","journal-title":"FASEB J"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302212?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302212?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,11]],"date-time":"2020-10-11T00:15:58Z","timestamp":1602375358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["S0924857917302212"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.04.014","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2017,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activity of innate antimicrobial peptides and ivacaftor against clinical cystic fibrosis respiratory pathogens","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}